Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01318174
Recruitment Status : Completed
First Posted : March 18, 2011
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Aleksander Talgøy Holten, Sykehuset Innlandet HF

Brief Summary:
The purpose of this study is to determine the prevalence of pulmonary embolism in our population of Chronic Obstructive Pulmonary Disease (COPD) patients admitted to hospital with dyspnea. The patients will undergo investigation for pulmonary embolism, according to current guidelines.

Condition or disease
Pulmonary Embolism Chronic Obstructive Pulmonary Disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 38 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease
Study Start Date : April 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Prevalence of pulmonary embolism in exacerbations of COPD [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology
Criteria

Inclusion Criteria:

  • known or suspected COPD
  • COPD-exacerbation

Exclusion Criteria:

  • other causes of dyspnea
  • unable to perform CT pulmonary angio (contrast allergy, pregnancy)
  • already included in the study (each patient included only once)
  • use of anticoagulants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01318174


Locations
Layout table for location information
Norway
Sykehuset Innlandet
Lillehammer, Oppland, Norway, 2381
Sponsors and Collaborators
Sykehuset Innlandet HF
Investigators
Layout table for investigator information
Principal Investigator: Aleksander T Holten, PhD Sykehuset Innlandet HF
Layout table for additonal information
Responsible Party: Aleksander Talgøy Holten, MD, Sykehuset Innlandet HF
ClinicalTrials.gov Identifier: NCT01318174    
Other Study ID Numbers: LE-KE
First Posted: March 18, 2011    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Keywords provided by Aleksander Talgøy Holten, Sykehuset Innlandet HF:
Pulmonary embolism
Pulmonary Disease, Chronic Obstructive
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Pulmonary Embolism
Embolism
Respiratory Tract Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases